Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of these two medications has not, however, been directly compared either clinically or preclinically. Further, whether or not a profound subjective existential experience is necessary for psilocybin to have antidepressant effects is unknown. To address these questions, we tested psilocybin, lysergic acid diethylamide (LSD), and ketamine in a rat model for depression. As in humans, a single administration of psilocybin or LSD produced persistent antidepressant-like effects in our model. In contrast, ketamine produced only a transient antidepressant-like effect. Our results indicate that classic psychedelics may have therapeutic efficacy that is more persistent than that of ketamine, and also suggest that a subjective existential experience may not be necessary for therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ketamine's effects on structural plasticity appear to last for approximately a week (150) while psilocybin's effects seem to be more durable lasting for at least a month (151, 152)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“This may explain why they have demonstrated efficacy in many preclinical rodent behavioral tests involving PFC circuitry including the forced swim test and fear extinction learning (151, 194–197).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“the mood-elevating properties of psilocybin seem to last significantly longer”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The use of the elevated plus maze as an assay of anxiety-related behavior in rodents
Walf, A. A., & Frye, C. A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.44 · Cited by 3,035
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Using the rat forced swim test to assess antidepressant-like activity in rodents
Slattery, D. A., & Cryan, J. F. (2012) · Nature Protocols · doi:10.1038/nprot.2012.044 · Cited by 903
Research works printed but not linked: 3
- Russell, 2009, The three Rs and the humanity criterion
- Hibicke, M. (2017) Development and Evaluation of an Adolescent Chronic Restraint Stress (ACRS) Protocol to Model Adult Depression in Female Rats. Ph.D. Thesis, Mercer University.
- Sengupta, 2013, The Laboratory Rat: Relating Its Age With Human’s, Int. J. Prev. Med., 4, 624
Cited by
Items 201–227 of 227
Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
Keenan, R. J., Haque, R. T., Jin, X., Mustafa, T., Homman‐Ludiye, J., Elysee, K., Wee, Z. S., Simonds, S. E., Foldi, C. J., & Cowley, M. A. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03995-7
Kleditzsch, N., Gattuso, J. J., Hannan, A. J., & Renoir, T. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70351
Effinger, D. P. (2023) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/5hmb-3772
Šabanović, M., & Lerch, J. P. (2022) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-54xkp76nk
Lane, C. P. (2025) · eScholarship@McGill (McGill) · doi:10.82308/37282
Pędzich, B. D. (2024) · VUBIR (Vrije Universiteit Brussel)
The effect of psilocybin on serotonergic activity and social behaviour
Pileggi, M. (2023) · eScholarship@McGill (McGill) · doi:10.82308/23547
Ezeaka, U. C. (2024) · HARVEST (University of Saskatchewan)
Rasannezhad, F., Daloii, A. A., Ziaolhagh, S. J., & Abdi, A. (2024) · Medical Laboratory Journal · doi:10.66224/mlj.18.6.36
“Methamphetamine was injected intraperitoneally at a dose of 15 mg every 12 hours for four days (22), and psilocybin was administered intraperitoneally at a dose of 1 mg/kg (19,23).”
InfluentialSubstanzgestützte Psychotherapie – Wege zur Legalisierung einer neuen Behandlung
Fritz, M. (2020) · Qucosa (Saxon State and University Library Dresden)
Woodruff, S., Hibicke, M., & Nichols, C. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251393186
“In contrast, a previous study by Hibicke et al. (2020) showed that weekly FST exposure for 5 weeks did not increase or decrease immobility in control rats.”
Self-citationSancilio, F. D., Dariani, M., Chavda, P., Rajagopal, H. M., & Tomlinson, L. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2607726
Presa, M. H. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Animal models in psychedelic research – Tripping over translation
Hay, M. Y. A. E., Cukić, A., Schölvinck, M. L., & Havenith, M. N. (2026) · Translational Psychiatry · doi:10.64898/2026.01.14.699469
“Similarly, psilocybin’s anxiolytic effects (quantified by the elevated plus maze task) only emerged when rats received repeated exposure to novel environments during the weeks following psilocybin administration (70).”
Olejnik, P., Kamińska, K., Gołembiowska, K., & Kasarełło, K. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00824-y
Psicodélicos en el tratamiento de la depresión: una revisión sobre eficacia y seguridad
Agudelo, S. I., Pérez, J. R. R., Gómez, J. G., & Barreneche, M. C. (2021) · Repositorio CES
Ascone, F., Giangiacomo, D., & Trezza, V. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106761
Ibi, D., Takaba, R., Yoshida, K., Kawase, R., Kitagawa, H., Matsushita, M., Ito, K., Uno, S., Nishimura, F., Kitagaki, S., et al. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70152
“Considering that the antidepressant effects of a single dose of psilocin/psilocybin have been reported to persist for several weeks in rodents [3, 17], a single administration of psilocin before CSDS onset may be sufficient to affect social behavior after the completion of CSDS, although psilocin…”
Buczma, K., Kamińska, K., Kasarełło, K., Mirowska-Guzel, D. M., Andrzejuk, D., Kaczmarek, A., & Cudnoch‐Jędrzejewska, A. (2026) · Biomedicines · doi:10.3390/biomedicines14071516
Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior
Narayan, S. V. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35588
Fleury, S., Chang, L. J., & Nautiyal, K. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.24.740586
“For example, contradictory effects of psilocybin have been reported on measures of behavioral despair such as the forced swim test (12–15) , with antidepressant-like effects varying considerably depending on the rodent model used (13,16,17).”
Seillier, A., Dannan, G. I. E., & Seillier, L. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111924
Savini, M. J., King, K. M., Puppel, L. P., Al-Olimat, A. K., Molnar, N. M., Schneider, E. J., Straub, S. E., Parker, J., Gottron, C. J., Bach, A. M., et al. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07188-4
Yu, A. N. C. (2026) · PhilPapers (PhilPapers Foundation)
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · doi:10.3389/fphar.2022.841648.s003
Metadata
- Authors
- Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D.
- Affiliations
- Louisiana State University (US)
- Corresponding author
- Nichols, Charles D.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-05
- Volume
- 11
- Issue
- 6
- Pages
- 864-871
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3010499243
- Cited by
- 205
- References
- 65
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 38 · 2023: 40 · 2022: 42 · 2021: 20 · 2020: 11
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Eleusis PBC (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, LSD, ketamine, psychedelics, antidepressant effects, depression, subjective experience, rat model of depression, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Depression, Hallucinogens, Ketamine, Rodentia, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.